Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Net Income towards Common Stockholders (2018 - 2025)

BioNexus Gene Lab's Net Income towards Common Stockholders history spans 8 years, with the latest figure at -$708991.0 for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders rose 47.3% year-over-year to -$708991.0; the TTM value through Sep 2025 reached -$2.3 million, down 155.62%, while the annual FY2024 figure was -$1.6 million, 39.2% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$708991.0 at BioNexus Gene Lab, down from -$616172.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $351515.0 in Q4 2023 and bottomed at -$2.6 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$77401.0 (2022), against an average of -$295045.4.
  • The largest YoY upside for Net Income towards Common Stockholders was 771.48% in 2023 against a maximum downside of 3271.0% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $115979.0 in 2021, then crashed by 145.14% to -$52349.0 in 2022, then soared by 771.48% to $351515.0 in 2023, then plummeted by 199.09% to -$348319.0 in 2024, then tumbled by 103.55% to -$708991.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Net Income towards Common Stockholders are -$708991.0 (Q3 2025), -$616172.0 (Q2 2025), and -$623327.0 (Q1 2025).